Profiling of miRNA expression in immune thrombocytopenia patients before and after Qishunbaolier (QSBLE) treatment

Burenbatu, Mandula Borjigin, Eerdunduleng, Wenyan Huo, Cuiqin Gong, Hasengaowa, Guiping Zhang, Longmei, Ming Li, Xuemei Zhang, Xiaohui Sun, Jie Yang, Shuanglian Wang, Narisu Narisu, Yangjian Liu, Haihua Bai

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is an autoimmune disease characterized by low platelet count and increased bleeding tendency. Currently, glucocorticoid and splenectomy are the main therapies for ITP but with obvious side effects including tendency of relapse and risk of internal bleeding. In this study, we report the Mongolian medicine Qishunbaolier (QSBLE) can significantly and efficiently increase platelet count with a low recurrent rate and unnoticeable side effect. We profiled the microRNA (miRNA) expression in the blood sample of ITP patients and identified 44 miRNAs that are differentially expressed in ITP patients before and after QSBLE treatment. Out of these 44 miRNAs, 25 are expressed in control subjects and are downregulated in ITP patients, whereas the treatment with QSBLE restores their expressions to the level of control subjects. This result suggests that abnormal expression of these 25 miRNAs might be connected to the pathogenesis of ITP. Interestingly, 14 of those 44 miNRAs are predicted to target at least once on 31 known IPT associated genes, indicating the possible mechanism of QSBLE on ITP therapy.

Original languageEnglish
Pages (from-to)196-204
Number of pages9
JournalBiomedicine and Pharmacotherapy
StatePublished - Oct 2015


  • Immune thrombocytopenia
  • MicroRNA expression
  • Mongolian medicine
  • Qishunbaolier treatment


Dive into the research topics of 'Profiling of miRNA expression in immune thrombocytopenia patients before and after Qishunbaolier (QSBLE) treatment'. Together they form a unique fingerprint.

Cite this